Kadimastem Finishes Treating Second Group of ALS Patients with AstroRx in Phase 1/2a Trial

Kadimastem has finished treating its second group of participants in a Phase 1/2a clinical trial testing the safety and preliminary efficacy of AstroRx, an investigational stem cell therapy for amyotrophic lateral sclerosis (ALS). AstroRx is an off-the-shelf cell therapy consisting…

Like many families, we played games over the holidays. Because my husband, Todd, is completely paralyzed due to ALS, we chose games in which he could participate. Apples to Apples worked well for him. I set his cards in the game’s box top, and he told me which card to…

A newly discovered self-destructive mechanism in mitochondria, the cells’  powerhouses, may be one of the first deficits leading to motor neuron degeneration associated with toxic TDP-43 clumps — a hallmark of amyotrophic lateral sclerosis (ALS). That evidence from a preclinical study suggests available therapies against mitochondrial degeneration might help halt neurodegeneration…

A machine-learning model based on insurance information from amyotrophic lateral sclerosis (ALS) patients may be able to speed diagnosis of the disease in others, research suggests. The findings were presented at the 30th International Symposium on ALS/MND, in the presentation “Machine learning model using insurance…

Last year, while serving as a moderator for the ALS News Today Forums, I added more than 355 people to my circle of ALS friends. And in the short time since the launch of the forums, it has become a trusted space where members can ask questions, share…

The founder of the END ALS Association, Masahiro “Hiro” Fujita, can no longer move and can barely communicate because of amyotrophic lateral sclerosis (ALS). To help him enjoy the holidays and to raise disease awareness, his organization launched the Merry & Bright — EEG Illumination project. The effort…

Sweden, a nation of 10 million people, is becoming a major force in European ALS research through the recent opening of a clinical trials facility at Stockholm’s Karolinska Institute and Karolinska University Hospital. Besides recruiting dozens of patients for trials there and in other countries, Swedish researchers…

ALS News Today brought you daily coverage of key findings, treatment developments, clinical trials, and other important events related to amyotrophic lateral sclerosis (ALS) throughout 2020, a year marked by the COVID-19 pandemic. As a…

For its promising investigational therapeutic approach to neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), BrainStorm Cell Therapeutics is the Buzz of BIO 2020 winner in the Public Therapeutic Biotech category. The Buzz of BIO contest identifies U.S. companies with groundbreaking, early-stage potential…

My Facebook friends post accomplishments like completing a 5K run. If I were to post my accomplishments, I would include taking my husband, Todd, to my daughter’s school concert. Going on a simple family outing with ALS can be challenging. With about 200 inches of snow falling annually, traveling is…